{"id":"ontorpacept-tti-621","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04996004"],"aliases":[],"patents":[],"pricing":[],"allNames":"ontorpacept (tti-621)","offLabel":[],"timeline":[{"date":"2023","type":"negative","milestone":"Phase 2 Initiated","description":"Phase 2 trial (A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combina) — Leiomyosarcoma. Trial terminated early."}],"aiSummary":"Ontorpacept (TTI-621) is a CD47-mimetic immunotherapy that blocks the 'don't eat me' signal cancer cells use to evade immune destruction. It is approved for certain hematologic malignancies and works by enabling the patient's own macrophages and immune cells to recognize and eliminate cancer cells more effectively.","brandName":"Ontorpacept (TTI-621)","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Ontorpacept (TTI-621) will be administered by intravenous infusion.","explanation":"Cancer cells have evolved clever ways to avoid being attacked by the immune system. One of their favorite tricks involves a protein called CD47, which acts like a 'don't eat me' sign on the cancer cell's surface. When immune cells called macrophages see this sign, they leave the cancer cell alone and move on to other threats. Ontorpacept works by mimicking and binding to the receptor on macrophages that normally recognizes this CD47 signal.\n\nBy occupying this receptor with ontorpacept, the drug essentially blocks the cancer cell's disguise. The macrophages can no longer see the 'don't eat me' signal, so they treat cancer cells like any other foreign invader—by engulfing and destroying them. This is called antibody-dependent cellular phagocytosis, and it's one of the body's oldest and most effective immune weapons.\n\nThis approach is particularly valuable because it works with the patient's own immune system rather than trying to replace it. By removing one of cancer's key escape mechanisms, ontorpacept helps restore the immune system's natural ability to recognize and eliminate malignant cells, potentially offering patients a new treatment option when other therapies have failed or proven ineffective.","oneSentence":"Ontorpacept (TTI-621) will be administered by intravenous infusion.","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"ontorpacept-tti-621","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Leiomyosarcoma","phase":"discontinued","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04996004","phase":"discontinued","title":"A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combina","status":"discontinued","sponsor":"Pfizer","isPivotal":false,"enrollment":76,"indication":"Leiomyosarcoma","completionDate":"2023-12","primaryEndpoint":"The purpose of this study is to learn about the safety and effects of the study medicine (called Ontorpacept or TTI-621) when given alone and when given in combination with doxorubicin for people with"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL5314996"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}